Vimarsana
Biggest News Aggregation in the World

About Primary Hyperoxaluria Type News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from About Primary Hyperoxaluria Type. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In About Primary Hyperoxaluria Type Today - Breaking & Trending Today

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1 - Alnylam Pharmaceuticals (NASDAQ:ALNY) - Press Release - Vimarsana News

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1 - Alnylam Pharmaceuticals (NASDAQ:ALNY) - Press Release

Published: October 7, 2022

- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patie

Source: wiredprnews.com
Related Topics:
United StatesUnited KingdomJorge CapapeyKim HollanderHyperoxaluria FoundationGlobal Rare Disease Lead At Alnylam PharmaceuticalsDrug AdministrationAlnylam Pharmaceuticals IncExchange CommissionAlnylam PharmaceuticalsEuropean Medicines AgencyCommittee For Medicinal Products Human UsePrimary Hyperoxaluria TypeLower UrinaryPlasma Oxalate LevelsAdult PatientsPositive EfficacySafety ResultsSevere Renal ImpairmentIncluding ThoseNew Drug ApplicationVice PresidentGlobal Rare Disease LeadMonth SixExecutive Director
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 - Vimarsana News

Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

Published: May 24, 2022

Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 - read this article along with other careers information, tips and advice on BioSpace

Source: biospace.com
Related Topics:
United KingdomUnited StatesFrance GeneralNoord HollandPushkal GargJaap GroothoffUniversity Of AmsterdamDrug AdministrationAlnylam Pharmaceuticals IncExchange CommissionAlnylam PharmaceuticalsInternational CongressAmerican Society Of NephrologyHead Of The Department Pediatric NephrologyEuropean Medicines AgencyEuropean Renal AssociationEuropean Renal Association DialysisTransplant AssociationProfessor Jaap GroothoffPediatric NephrologyGemma ChildrenChief Medical OfficerAmerican SocietyKidney Week MeetingEnhanced Stabilization Chemistry